Summary of Key Points Core Viewpoint - The report outlines the non-operating fund occupation and other related fund transactions of Xintiandi Pharmaceutical Co., Ltd. for the first half of 2025, highlighting the financial interactions with related parties and the overall financial health of the company. Group 1: Non-operating Fund Occupation - The total amount of non-operating fund occupation for the first half of 2025 is not specified in the provided data, indicating a potential lack of financial strain from this aspect [1]. - The report includes details on the nature of fund occupation, which is primarily related to the company's controlling shareholders and their affiliated enterprises [1]. Group 2: Related Fund Transactions - The total amount of related fund transactions for the first half of 2025 is also not specified, suggesting that the company maintains a stable financial relationship with its affiliates [2]. - Specific transactions include accounts receivable and payable with subsidiaries, indicating ongoing operational interactions that are essential for the company's business continuity [2]. Group 3: Financial Approval and Oversight - The report was approved by the sixth board of directors' seventh meeting on August 9, 2025, ensuring that the financial activities are under proper governance [2]. - The legal representative and the head of accounting are responsible for the accuracy of the financial data presented, reflecting the company's commitment to transparency and accountability [2].